PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-8.13
Negative P/E while Drug Manufacturers - Specialty & Generic median is -0.56. Seth Klarman would scrutinize path to profitability versus peers.
21.12
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.08. Jim Chanos would check for potential multiple compression risks.
1.77
P/B near Drug Manufacturers - Specialty & Generic median of 1.75. Charlie Munger would verify if similar multiples reflect similar business quality.
-109.61
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
-644.02
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
1.77
Fair value ratio near Drug Manufacturers - Specialty & Generic median of 1.76. Charlie Munger would verify if industry valuation norms make sense.
-3.07%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -0.13%. Seth Klarman would investigate path to profitability.
-0.91%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.